Comments
Shares of drugmaker Dr Reddy’s Lab fell as much as 6.7% to Rs 2,571 ; their biggest intraday loss since February 15, amidst a market rally.
The broader NSE index was up 2.75% at 11,721.95 , while the benchmark BSE index rose 2.82% to 38,998.90, post exit polls
The March-quarter revenue for Dr Reddy's rises to Rs 4,017 crore from Rs 3,535 crore, but numbers fell below analysts' estimates
Nomura says revenue, EBITDA misses its estimates by 2% and 31%, respectively, despite exceptional gains.
Nomura reduces estimates for FY20 and FY21 by 10% and 7%, respectively, on delays in approval for launch of multiple sclerosis treatment Copaxone and contraceptive device Nuvaring
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.